A report of the panels recommendations, Oral Semaglutide for Type 2 Diabetes: Final Policy Recommendations, was published December 9, 2019 along with ICERs Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value, Final Evidence Report. ICER is an independent non-profit research organization
This leads to changes in energy substrate use, favoring the utilization of lipids for energy production [45]
Many mild injection site reactions do not require stopping treatment
You should contact your GP or diabetes specialist nurse if you experience: Significant skin changes that cause distress or affect your quality of life, as this may impact treatment adherence Skin breakdown, ulceration, or persistent redness in areas of loose skin, which could indicate infection or other complications Consistent weight loss exceeding 1 kg per week for several weeks, which may require dose adjustment or additional nutritional support Signs of nutritional deficiency , such as brittle nails, hair loss, or unusual fatigue, which may accompany inadequate dietary intake Concerns about injection site reactions , including lumps, persistent bruising, or changes in skin texture at injection sites Seek urgent medical attention if you develop: Severe, persistent abdominal pain (possibly radiating to the back), which could indicate pancreatitis Yellowing of the skin/eyes, fever or severe abdominal pain, which might suggest gallbladder problems Persistent vomiting or signs of dehydration Sudden visual changes, especially if you have pre-existing diabetic retinopathy Symptoms of low blood sugar (hypoglycaemia) if you also take insulin or sulfonylureas Your healthcare provider can assess whether your weight loss is occurring at an appropriate rate and ensure you are receiving adequate nutritional support
%25201.png)
